Stock Taper Q4 Adjusted Diluted Loss Per Share: $1.19
Full Year Adjusted Diluted EPS: $2.08
GAAP Diluted Loss Per Share: $2.24, impacted by a $389 million loss from divesting the remaining Magellan business.
Total Premium and Service Revenue: $174.6 billion for the year.
Health Benefits Ratio (HBR):
Medicaid: 93% in Q4, showing a 190 basis points improvement from Q2.
Marketplace: Slightly higher than expectations due to out-of-period items.
Membership: Medicaid membership at 12.5 million, with a projected decline in 2026.
Medicaid: Focused on restoring profitability through improved execution and quality outcomes. Key initiatives include optimizing networks, implementing clinical programs, and enhancing fraud detection.
Marketplace: Experienced a shift towards more bronze plan enrollments (30% of membership), with proactive pricing strategies in response to market changes.
Medicare: Strong performance in Medicare Advantage and Part D, with a goal of breakeven in Medicare Advantage by 2027. Adjustments made to provider contracts to improve profitability.
2026 Adjusted EPS Guidance: Expected to exceed $3, representing over 40% year-over-year growth.
Revenue Projections: Anticipated premium and service revenue between $170 billion and $174 billion.
Medicaid HBR: Expected to remain stable at around 93% for 2026.
Marketplace Membership: Projected to decline to approximately 3.5 million by Q1 2026.
Medicare Segment Growth: Expected to grow by approximately $7.5 billion, driven by increased membership and premium yield.
Membership Attrition: Anticipated decline in Medicaid membership due to tighter eligibility criteria and program changes, with a projected 5-6% reduction in member months.
Marketplace Pressures: The expiration of enhanced advanced premium tax credits (APTCs) may lead to increased market volatility and impact profitability.
Medicare Rate Pressure: The 2027 advance notice suggests a more pressured view of rates, potentially affecting benefits and product selection for seniors.
Competitive Dynamics: Ongoing margin pressures in Medicaid may lead to exits from the market by smaller plans, impacting overall competition and service quality.
Medicaid Rate Assumptions: Management expressed confidence in a conservative 4.5% rate increase for 2026, supported by two years of data on acuity and trends.
Marketplace Dynamics: The shift towards bronze plans is seen as a market response, with early indications showing no alarming utilization patterns among these members.
PBM Contract: The flexible and tailored contract with their PBM partner is expected to provide economic benefits and support margin targets across segments.
Medicare Advantage Breakeven: No premium deficiency reserve (PDR) in 2026 suggests progress towards breakeven, although slight losses are still anticipated. Overall, Centene is navigating a challenging landscape but is optimistic about restoring profitability and improving margins across its segments in 2026, while also addressing membership attrition and competitive pressures.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT